Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study)

Zeuschner P, Hoelters S, Stoeckle M, Seliger B, Mueller A, Bachmann HS, Gruenwald V, Christoph DC, Stenzl A, Grimm MO, Bruening F, Goebell P, Augustin M, Roos F, Harde J, Benz-Rued I, Staehler M, Junker K (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 99-99

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

Universität des Saarlandes (UdS) DE Germany (DE) Universitätsklinikum Jena DE Germany (DE) iOMEDICO AG DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Paracelsus Medizinische Privatuniversität AT Austria (AT) Universität Witten/Herdecke DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Martin-Luther-Universität Halle-Wittenberg (MLU) DE Germany (DE) Philipps-Universität Marburg DE Germany (DE)

How to cite

APA:

Zeuschner, P., Hoelters, S., Stoeckle, M., Seliger, B., Mueller, A., Bachmann, H.S.,... Junker, K. (2022). Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study). In ONCOLOGY RESEARCH AND TREATMENT (pp. 99-99). BASEL: KARGER.

MLA:

Zeuschner, Philip, et al. "Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 99-99.

BibTeX: Download